This study develops tools to measure LRRK2 activity and expression in immune cells relevant to Crohn’s disease, revealing ...

Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, getting a green light in China for sacituzumab tirumotecan (sac-TMT).

Products Market Alerts MyCollection Price Database Become a Partner Gallery ...

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.